<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01122888</url>
  </required_header>
  <id_info>
    <org_study_id>NCI-2011-01455</org_study_id>
    <secondary_id>NCI-2011-01455</secondary_id>
    <secondary_id>CDR0000659080</secondary_id>
    <secondary_id>UCCRC-09-259-A</secondary_id>
    <secondary_id>09-259-A</secondary_id>
    <secondary_id>8313</secondary_id>
    <secondary_id>P30CA014599</secondary_id>
    <secondary_id>U01CA069852</secondary_id>
    <nct_id>NCT01122888</nct_id>
  </id_info>
  <brief_title>Cilengitide and Sunitinib Malate in Treating Patients With Advanced Solid Tumors or Glioblastoma Multiforme</brief_title>
  <official_title>Pilot Biomarker Study of the Integrin AlphavBeta3 Antagonist Cilengitide (EMD121974) in Combination With Sunitinib</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>National Cancer Institute (NCI)</agency>
      <agency_class>NIH</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>National Cancer Institute (NCI)</source>
  <brief_summary>
    <textblock>
      This clinical trial is studying how well giving cilengitide together with sunitinib malate&#xD;
      works in treating patients with advanced solid tumors or glioblastoma multiforme. Cilengitide&#xD;
      and sunitinib malate may stop the growth of tumor cells by blocking blood flow to the tumor.&#xD;
      Giving cilengitide together with sunitinib malate may kill more tumor cells. Studying samples&#xD;
      of blood in the laboratory from patients receiving cilengitide and sunitinib malate may help&#xD;
      doctors understand the effect of these drugs on biomarkers.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      PRIMARY OBJECTIVES:&#xD;
&#xD;
      I. Determine the effect of cilengitide on changes in serum VEGFR2, a pharmacodynamic&#xD;
      biomarker of sunitinib malate effects on endothelial function, during the withdrawal phase of&#xD;
      a course of sunitinib malate in patients with advanced solid tumors or glioblastoma&#xD;
      multiforme.&#xD;
&#xD;
      SECONDARY OBJECTIVES:&#xD;
&#xD;
      I. Determine the effect of cilengitide exposure on changes in VEGFR2 over the 14-day interval&#xD;
      from the end of sunitinib malate administration to the end of course 1 in these patients.&#xD;
&#xD;
      II. Test the safety and efficacy of this regimen in these patients. III. Develop serum&#xD;
      collagen c-telopeptide crosslinks (CTx) as a pharmacodynamic marker for cilengitide.&#xD;
&#xD;
      OUTLINE:&#xD;
&#xD;
      COURSE I: Patients receive oral sunitinib malate on days 1-14 (weeks 1-2). Patients are then&#xD;
      randomized to 1 of 2 treatment arms.&#xD;
&#xD;
      ARM I: Patients receive cilengitide IV over 1 hour twice in weeks 3 and 4.&#xD;
&#xD;
      ARM II: Patients do not receive treatment in weeks 3 and 4.&#xD;
&#xD;
      COURSE II: Patients in both arms then receive oral sunitinib malate on days 1-14 and&#xD;
      cilengitide IV over 1 hour twice in weeks 3 and 4. Treatment repeats every 4 weeks in the&#xD;
      absence of disease progression or unacceptable toxicity.&#xD;
&#xD;
      After completion of study therapy, patients are followed up periodically.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Terminated</overall_status>
  <start_date>December 2009</start_date>
  <completion_date type="Actual">April 2015</completion_date>
  <primary_completion_date type="Actual">September 2012</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Change in serum VEGFR2</measure>
    <time_frame>Over 14 days from the end of sunitinib to the end of course 1</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Comparison of the change in serum VEGFR2 in courses 1 and 2</measure>
    <time_frame>Over 14 days</time_frame>
    <description>Compared using a paired t-test.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Progression-free survival</measure>
    <time_frame>Assessed up to 30 days after completion of study treatment</time_frame>
    <description>Estimated using the Kaplan-Meier method. Summarized by type, grade, and attribution and compared using chi-squared tests or Fisher exact tests, as appropriate.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Response rate evaluated using RECIST criteria</measure>
    <time_frame>Up to 30 days after completion of study treatment</time_frame>
    <description>Summarized by type, grade, and attribution and compared using chi-squared tests or Fisher exact tests, as appropriate.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Serum type I collagen c-telopeptide crosslink measurements</measure>
    <time_frame>Up to 30 days after completion of study treatment</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Toxicity rates, graded using the NCI CTCAE version 4.0</measure>
    <time_frame>Up to 30 days after completion of study treatment</time_frame>
    <description>Compared using chi-squared tests or Fisher exact tests, as appropriate.</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">41</enrollment>
  <condition>Adult Giant Cell Glioblastoma</condition>
  <condition>Adult Glioblastoma</condition>
  <condition>Adult Gliosarcoma</condition>
  <condition>Adult Solid Neoplasm</condition>
  <condition>Recurrent Adult Brain Neoplasm</condition>
  <arm_group>
    <arm_group_label>Arm I (course 1)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Patients receive cilengitide IV over 1 hour twice weekly for 2 weeks.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Arm II (course 1)</arm_group_label>
    <arm_group_type>Other</arm_group_type>
    <description>Patients do not receive treatment and undergo a 2-week rest period.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Cilengitide</intervention_name>
    <description>Given IV</description>
    <arm_group_label>Arm I (course 1)</arm_group_label>
    <other_name>EMD 121974</other_name>
    <other_name>EMD-121974</other_name>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Clinical Observation</intervention_name>
    <description>Patients undergo a 2-week rest period</description>
    <arm_group_label>Arm II (course 1)</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Laboratory Biomarker Analysis</intervention_name>
    <description>Correlative studies</description>
    <arm_group_label>Arm I (course 1)</arm_group_label>
    <arm_group_label>Arm II (course 1)</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Histologically confirmed solid tumor or malignant glioblastoma multiforme meeting &gt;= 1&#xD;
             of the following criteria:&#xD;
&#xD;
               -  Disease refractory to standard therapy&#xD;
&#xD;
               -  No standard therapy exists&#xD;
&#xD;
               -  Sunitinib malate monotherapy would be appropriate management&#xD;
&#xD;
          -  Measurable disease is not required&#xD;
&#xD;
          -  Previously treated brain metastases or primary brain neoplasms allowed provided&#xD;
             patient is not receiving concurrent corticosteroids&#xD;
&#xD;
          -  Karnofsky performance status 70-100%&#xD;
&#xD;
          -  Absolute neutrophil count (ANC) &gt;= 1,500/μL&#xD;
&#xD;
          -  White blood cell count (WBC) &gt;= 3,000/μL&#xD;
&#xD;
          -  Platelet count &gt;= 100,000/μL&#xD;
&#xD;
          -  Hemoglobin &gt;= 9 g/dL&#xD;
&#xD;
          -  Total bilirubin normal (unless due to documented Gilbert syndrome)&#xD;
&#xD;
          -  Aspartate aminotransferase (AST) and alanine aminotransferase (ALT) &lt; 2.5 times upper&#xD;
             limit of normal (ULN) (&lt; 5 times ULN in the presence of liver metastases)&#xD;
&#xD;
          -  Creatinine normal OR creatinine clearance &gt;= 60 mL/min&#xD;
&#xD;
          -  Serum calcium =&lt; 12.0 mg/dL&#xD;
&#xD;
          -  QTc &lt; 500 msec&#xD;
&#xD;
          -  Patients with any of the following are allowed provided they have New York Heart&#xD;
             Association (NYHA) class I-II cardiac function and undergo a baseline echocardiogram&#xD;
             (ECHO)/multiple gated acquisition (MUGA):&#xD;
&#xD;
               -  History of class II heart failure and asymptomatic on treatment&#xD;
&#xD;
               -  Prior anthracycline exposure&#xD;
&#xD;
               -  Previously treated with central thoracic radiotherapy that included the heart in&#xD;
                  the radiotherapy port&#xD;
&#xD;
          -  Not pregnant or nursing&#xD;
&#xD;
          -  Negative pregnancy test&#xD;
&#xD;
          -  Fertile patients must use effective barrier contraception&#xD;
&#xD;
          -  No history of allergic reactions attributed to compounds of similar chemical or&#xD;
             biologic composition to sunitinib malate&#xD;
&#xD;
          -  No concurrent uncontrolled illness including, but not limited to, any of the&#xD;
             following:&#xD;
&#xD;
               -  Ongoing or active infection&#xD;
&#xD;
               -  Symptomatic congestive heart failure&#xD;
&#xD;
               -  Unstable angina pectoris&#xD;
&#xD;
               -  Cardiac arrhythmia&#xD;
&#xD;
               -  Psychiatric illness and/or social situation that would limit compliance with&#xD;
                  study requirements&#xD;
&#xD;
          -  No pre-existing thyroid abnormality for which thyroid function cannot be maintained in&#xD;
             the normal range with medication&#xD;
&#xD;
          -  No documented thrombosis (pulmonary embolism or deep vein thrombosis) within the past&#xD;
             6 months&#xD;
&#xD;
          -  No known coagulopathy or thrombophilia&#xD;
&#xD;
          -  No proven gastric or duodenal ulcer or clinically significant gastrointestinal (GI)&#xD;
             blood loss within the past 6 weeks&#xD;
&#xD;
          -  No history of central nervous system (CNS) hemorrhage&#xD;
&#xD;
          -  No life-threatening bleeding diathesis within the past 6 months&#xD;
&#xD;
          -  No history of serious ventricular arrhythmia (i.e., ventricular fibrillation or&#xD;
             ventricular tachycardia &gt;= 3 beats in a row) or other significant electrocardiogram&#xD;
             (ECG) abnormalities&#xD;
&#xD;
          -  No poorly controlled hypertension (i.e., systolic blood pressure (BP) &gt;= 150 mm Hg or&#xD;
             diastolic BP &gt;= 100 mm Hg)&#xD;
&#xD;
          -  No condition that would impair the ability to swallow and retain sunitinib malate&#xD;
             tablets, including any of the following:&#xD;
&#xD;
               -  GI tract disease resulting in an inability to take oral medications or a&#xD;
                  requirement for IV alimentation&#xD;
&#xD;
               -  Prior surgical procedures affecting absorption&#xD;
&#xD;
               -  Active peptic ulcer disease&#xD;
&#xD;
          -  No gastrostomy, jejunostomy, or other forms of enteral tube feeding modalities&#xD;
&#xD;
          -  None of the following conditions:&#xD;
&#xD;
               -  Serious or non-healing wound or ulcer&#xD;
&#xD;
               -  Abdominal fistula, GI perforation, or intra-abdominal abscess within the past 28&#xD;
                  days&#xD;
&#xD;
               -  Cerebrovascular accident or transient ischemic attack within the past 12 months&#xD;
&#xD;
               -  Myocardial infarction, cardiac arrhythmia, stable/unstable angina, symptomatic&#xD;
                  congestive heart failure, or coronary/peripheral artery bypass graft or stenting&#xD;
                  within the past 12 months&#xD;
&#xD;
               -  NYHA class III or IV heart failure&#xD;
&#xD;
               -  Radiographically or physiologically diagnosed usual interstitial pneumonitis&#xD;
                  (UIP) or non-specific interstitial pneumonitis (NSIP)&#xD;
&#xD;
          -  No bone fracture within the past 12 months&#xD;
&#xD;
          -  No other concurrent anticancer agents or therapies&#xD;
&#xD;
          -  More than 4 weeks since prior radiotherapy or systemic antineoplastic therapy (6 weeks&#xD;
             for nitrosoureas, mitomycin C, or bevacizumab) and recovered&#xD;
&#xD;
          -  More than 2 weeks since prior hormone replacement therapy or hormonal contraceptives&#xD;
&#xD;
          -  More than 1 month since prior surgery&#xD;
&#xD;
          -  At least 7 days since prior and no concurrent CYP3A4 inhibitors&#xD;
&#xD;
          -  At least 12 days since prior and no concurrent CYP3A4 inducers&#xD;
&#xD;
          -  Prior luteinizing hormone-releasing hormone agonists for hormone-refractory prostate&#xD;
             cancer allowed&#xD;
&#xD;
          -  Prior antiangiogenic agents (e.g., sorafenib, pazopanib, AZD2171 [cediranib maleate],&#xD;
             PTK787 [vatalanib], or VEGF Trap [ziv-aflibercept]) allowed provided there is no&#xD;
             disease progression&#xD;
&#xD;
          -  No prior cilengitide or sunitinib malate&#xD;
&#xD;
          -  No prior bevacizumab&#xD;
&#xD;
          -  No other concurrent investigational agents&#xD;
&#xD;
          -  No concurrent combination antiretroviral therapy for human immunodeficiency virus&#xD;
             (HIV)-positive patients&#xD;
&#xD;
          -  No concurrent agents with proarrhythmic potential (e.g., terfenadine, quinidine,&#xD;
             procainamide, disopyramide, sotalol, probucol, bepridil, haloperidol, risperidone,&#xD;
             indapamide, or flecainide)&#xD;
&#xD;
          -  No concurrent palliative radiotherapy&#xD;
&#xD;
          -  No other concurrent chemotherapy or biologic agents&#xD;
&#xD;
          -  No concurrent medications that may cause QTc prolongation&#xD;
&#xD;
          -  No concurrent therapeutic doses of coumarin-derivative anticoagulants (e.g., warfarin)&#xD;
&#xD;
               -  Up to 2 mg of daily warfarin for the prophylaxis of thrombosis allowed&#xD;
&#xD;
               -  Low-molecular weight heparin allowed provided prothrombin time (PT)/international&#xD;
                  normalized ratio (INR) =&lt; 1.5&#xD;
&#xD;
          -  No concurrent grapefruit juice&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Michael Maitland</last_name>
    <role>Principal Investigator</role>
    <affiliation>University of Chicago Comprehensive Cancer Center</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>University of Chicago Comprehensive Cancer Center</name>
      <address>
        <city>Chicago</city>
        <state>Illinois</state>
        <zip>60637</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>April 2015</verification_date>
  <study_first_submitted>January 12, 2010</study_first_submitted>
  <study_first_submitted_qc>May 11, 2010</study_first_submitted_qc>
  <study_first_posted type="Estimate">May 13, 2010</study_first_posted>
  <last_update_submitted>April 27, 2015</last_update_submitted>
  <last_update_submitted_qc>April 27, 2015</last_update_submitted_qc>
  <last_update_posted type="Estimate">April 28, 2015</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Neoplasms</mesh_term>
    <mesh_term>Glioblastoma</mesh_term>
    <mesh_term>Gliosarcoma</mesh_term>
    <mesh_term>Brain Neoplasms</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

